These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22313294)

  • 1. 3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
    Raichurkar AV; Shah UA; Kulkarni VM
    Med Chem; 2011 Nov; 7(6):543-52. PubMed ID: 22313294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
    Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
    Barberot C; Moniot A; Allart-Simon I; Malleret L; Yegorova T; Laronze-Cochard M; Bentaher A; Médebielle M; Bouillon JP; Hénon E; Sapi J; Velard F; Gérard S
    Eur J Med Chem; 2018 Feb; 146():139-146. PubMed ID: 29407945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive QSAR modeling of phosphodiesterase 4 inhibitors.
    Kovalishyn V; Tanchuk V; Charochkina L; Semenuta I; Prokopenko V
    J Mol Graph Model; 2012 Feb; 32():32-8. PubMed ID: 22023934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
    Huang L; Shan W; Zhou Q; Xie J; Lai K; Li X
    Bioorg Med Chem Lett; 2014 Jan; 24(1):249-53. PubMed ID: 24300734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
    Gaurav A; Singh R
    Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors.
    Balasubramanian G; Narayanan S; Andiappan L; Sappanimuthu T; Thirunavukkarasu S; Sundaram S; Natarajan S; Sivaraman N; Rajagopal S; Nazumudeen FAA; Saxena S; Vishwakarma SL; Narayanan S; Sharma GVR; Srinivasan CV; Kilambi N
    Bioorg Med Chem; 2016 Nov; 24(22):5702-5716. PubMed ID: 27713015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors.
    Chakraborti AK; Gopalakrishnan B; Sobhia ME; Malde A
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2473-9. PubMed ID: 12852946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation.
    Wagh NK; Deokar HS; Juvale DC; Kadam SS; Kulkarni VM
    Indian J Biochem Biophys; 2006 Dec; 43(6):360-71. PubMed ID: 17285800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study.
    Huang C; Zhong QP; Tang L; Wang HT; Xu JP; Zhou ZZ
    Chem Biol Drug Des; 2019 Apr; 93(4):484-502. PubMed ID: 30588755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.
    Guariento S; Bruno O; Fossa P; Cichero E
    Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
    Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
    Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 1,2,4-triazolo[1,5-a]pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activity.
    Abd El-Aleam RH; George RF; Lee KJ; Keeton AB; Piazza GA; Kamel AA; El-Daly ME; Hassan GS; Abdel-Rahman HM
    Arch Pharm (Weinheim); 2019 Aug; 352(8):e1900002. PubMed ID: 31353608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
    Gouault N; Pinel B; Cupif JF; Depince A; Martin-Chouly CA; Belleguic C; David M
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):475-80. PubMed ID: 15662951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Hatzelmann A; Van Klink GP; Van der Laan IJ; Sterk GJ; Thibaut U; Ulrich WR; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2523-35. PubMed ID: 11472206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
    Guo YQ; Tang GH; Lou LL; Li W; Zhang B; Liu B; Yin S
    Eur J Med Chem; 2018 Jan; 144():758-766. PubMed ID: 29291443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.
    Chakraborti AK; Gopalakrishnan B; Sobhia ME; Malde A
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1403-8. PubMed ID: 12668000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR.
    Antunes JE; Freitas MP; Rittner R
    Eur J Med Chem; 2008 Aug; 43(8):1632-8. PubMed ID: 18045743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.